SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

CORRESP Filing

Lexeo Therapeutics, Inc.
Date: June 27, 2025 · CIK: 0001907108 · Accession: 0001193125-25-151402

Offering / Registration Process

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-288025

Date
June 27, 2025
Author
Jenny R. Robertson
Form
CORRESP
Company
Lexeo Therapeutics, Inc.

Letter

Re: Lexeo Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-288025 Acceleration Request Requested Date: June 30, 2025 Requested Time: 4:00 P.M. Eastern Time Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Lexeo Therapeutics, Inc. (the “ Company ”) hereby requests that the above-referenced Registration Statement on Form S-3 (File No. 333-288025) (the “ Registration Statement ”) be declared effective at the “Requested Date” and “Requested Time” set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Wilson Sonsini Goodrich & Rosati, P.C., by calling Megan J. Baier at (212) 497-7736.

Lexeo Therapeutics, Inc. 345 Park Avenue South, Floor 6 New York, New York 10010 June 27, 2025 VIA EDGAR U.S. Securities and Exchange Commission Office of Life Sciences Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720

Sincerely,
LEXEO THERAPEUTICS, INC.

Show Raw Text
CORRESP
 1
 filename1.htm

 CORRESP

 Lexeo Therapeutics, Inc.
 345 Park Avenue South, Floor 6 New
York, New York 10010 June 27, 2025 VIA EDGAR
 U.S. Securities and Exchange Commission Office of Life
Sciences Division of Corporation Finance 100 F Street, N.E.
 Washington, D.C. 20549-3720

 Re:
 Lexeo Therapeutics, Inc.
 Registration Statement on Form S-3
 File No. 333-288025
 Acceleration Request Requested Date:
June 30, 2025 Requested Time: 4:00 P.M. Eastern Time
 Ladies and Gentlemen: Pursuant to Rule 461 under the
Securities Act of 1933, as amended, Lexeo Therapeutics, Inc. (the “ Company ”) hereby requests that the above-referenced Registration Statement on Form S-3 (File
 No. 333-288025) (the “ Registration Statement ”) be declared effective at the “Requested Date” and “Requested Time” set forth above or at such later time as the Company
or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Once the Registration Statement has been declared effective, please orally confirm that event with
our counsel, Wilson Sonsini Goodrich & Rosati, P.C., by calling Megan J. Baier at (212) 497-7736.

 Sincerely,

 LEXEO THERAPEUTICS, INC.

 /s/ Jenny R. Robertson

 Jenny R. Robertson

 Chief Legal Officer

 cc:
 R. Nolan Townsend
 Lexeo Therapeutics, Inc.
 Megan J. Baier David G. Sharon
 Wilson Sonsini Goodrich & Rosati, P.C.